About Us

Company Information

Pharma Equity Group, listed on the
Nasdaq Copenhagen Stock Exchange, places a strong emphasis on its portfolio company, Reponex Pharmaceuticals A/S. As a clinical-stage biopharmaceutical company, Reponex Pharmaceuticals is dedicated to developing innovative and effective treatments for diseases that have a profound impact on patients and society, especially in cases where current therapies are lacking or require improvement.

Pharma Equity Group’s primary focus lies in supporting and nurturing the growth of Reponex Pharmaceuticals within its portfolio. The company actively collaborates with Reponex Pharmaceuticals
to help achieve its goals, leveraging the expertise of its experienced
professionals in the life science industry, investment, and business

With a specialized investment focus
on early-stage biotechnology companies, Pharma Equity Group recognizes the potential of Reponex Pharmaceuticals’ novel therapies for unmet medical needs.
By maintaining Reponex Pharmaceuticals within its portfolio, Pharma Equity Group ensures a dedicated and strategic approach to driving its success.

Furthermore, Pharma Equity Group’s
network of industry partners and advisors strengthens its commitment to Reponex Pharmaceuticals’ growth and development. The company’s overall strategy emphasizes creating a cost-efficient and flexible environment, enabling rapid
mobilization of relevant resources—a key factor that drives the success of Reponex Pharmaceuticals’ innovative initiatives.


Pharma Equity Group, formerly Blue Vision, is listed on the main list on the Nasdaq Copenhagen Stock Exchange.

On 5 April 2022, Pharma Equity Group launched a conditional takeover offer to the shareholders of Reponex Pharmaceuticals A/S (“Reponex”).

On 27 February 2023, the transaction with Reponex was approved by The Danish Financial Supervisory Authority and Nasdaq Copenhagen.

First trading day for newly issued shares on Nasdaq Copenhagen is 28th of March 2023.

Board of Directors

Christian Vinding Thomsen

Chairman of the Board

Peter Vilmann

Board Member

Lars Gundorph

Board Member


To support the Board in its duties, the Board has established and appointed an Audit Committee, a Remuneration Committee, a Nomination Committee and a Business, Research and Development Committee. These committees will be charged with reviewing issues pertaining to their respective fields that are due to be considered at board meetings.

Meetings will be held to a minimum of 4 meetings per year or as often as requested by a member of the Committee or by the Company’s external auditor according to a specific event/challenge. The Committee only passes resolutions where recommendations are to be made to the Board of Directors.


The Committees have no independent decision-making power. All resolutions by the Committees must be passed by a simple majority of votes. Minutes of all Committees meetings must be prepared at the latest 5 days after the meeting. The Committees’ nominations and recommendations to the Board of Directors must be set out clearly in the minutes, including their reasons. 

Audit Committee

The Audit Committee is established with the purpose of assisting the Board of Directors with the monitoring of the financial reporting process, the statutory audit of the Company’s financial reports (including the process for presentation of accounts), internal control and risk management systems and the Company’s whistleblowing procedures and complaints. The Audit Committee shall also assess the external auditor’s independence and provision of services and the procedure for the election of the external auditor, and annually consider whether there is a need for an internal audit and if so, submit a recommendation to the Board of Directors in this respect including recommendations regarding the appointment, employment and dismissal of the chairman of any internal audit and the budget of the internal audit. The Audit Committee is expected to comply with the Danish Corporate Governance Recommendations Sections 3.4.2 and 3.4.3.

The specific assignments of the Audit Committee are:

·         The financial reporting processes

o    To ensure that the financial information presented in the Pharma Equity Group’s annual and interim financial reports provides the basis and correctness of financial information, which can make basis for existing and future shareholders’ decision-making, regarding investment in the current and future companies in the portfolio.

o    To ensure a high degree of efficiency in the financial reporting processes.

o    To assess and if necessary, investigate Management’s actions and assessments for the annual and interim financial reporting before they are submitted to the Board of Directors.

o    Review assessment and explanation of the central conclusions in the annual financial reports, interim reports and forecast, including drafts of the board’s report on the same reports prior to the board’s review.

·         The external audits

o    To make a critical assessment of the independence, objectivity, and competence of the external auditors in relation to, among others, audit and supply of additional services to the Company.

o    Review and assess the draft of the audit protocol with the external auditors.

o    Review of the external auditors’ audit plan and review of the financial departments’ plan for finalizing the financial reports.

o    To submit recommendations to the Board of Directors for its recommendation to the general meeting on the appointment of external auditors.

·         Investment and financing policies

o    Control and monitoring of the investment- and financing policies and future strategies, including the degree of debt financing and the underlying factors such as interest rate risk and refinancing risk as well as assessment of the financial reserves.

·         The internal control and risk management systems

    • Continuous monitoring of the company’s internal control and risk management systems and procedures.

Christian Vinding Thomsen

Chairman of the Audit Committee

Nomination and Remuneration Committee

The Nomination and Remuneration Committee has as its objective, to improve the quality of the work of the Board of Directors by contributing to the preparation of the basis for the Board’s decisions regarding nomination and appointments of new members of the Board of Directors and the Executive management.

The Nomination Committee is expected to comply with the Danish Corporate Governance Recommendations Sections 3.4.2 and 3.4.5.

The specific assignments of the Nomination and Remuneration Committee are:

  • The nomination and appointment of members of the Board of Directors and Executive Management, including general guidelines on incentive pay.

  • Ensure that the Board of Directors and the Executive Management always have the required qualifications and experience.

  • The conduct of regular evaluations of the Board of Directors’ and the Executive Management’s performance; and the drawing up, implementation and pursuit of the remuneration policy for members of the Board of Directors and the Executive Management.

  • Monitor the annual report’s remuneration information.

Lars Gundorph

Chairman of the Nomination and Renumeration Committee

The Business, Research and Development Committee

The committee is established to assist the Board of Directors in monitoring and reviewing the company’s research, technologies, products, pipeline, clinical trials, supply chain management and business strategies.

The Committee has as its objective to improve the Board of Directors decision making according to make the optimal business-, research- and development decisions as well as a future strategy for the same areas, for the company.

The specific assignments of the Business, Research and Development Committee are:

  • Reviewing and assessing the Company’s research and development (“R&D”) programs to develop investment strategies with the Board and Executive Management.

  • Monitoring and overseeing the Company’s progress in achieving R&D goals and objectives, and making recommendations to the Supervisory Board on modifications to the Company’s R&D goals and objectives.

  • Performing strategic reviews of the Company’s key R&D programs as well as the scientific and R&D aspects of licensing, strategic partnerships, and acquisition or divestiture transactions.

  • Reviewing the company’s scientific publication and communications plan.

  • Reviewing and assessing the Company’s intellectual property portfolio and strategy.

  • Evaluating and challenging the effectiveness and competitiveness of the research and development endeavors of the Company.

  • Overseeing management’s exercise of its responsibility to assess and manage risks associated with the Company’s R&D programs and regulatory matters.

  • Identifying and reporting to the Supervisory Board on significant emerging science and technology issues and trends that may impact the Company.

  • Serving as a resource for management to consult on any such topics regarding scientific and regulatory matters as reasonably requested.

Peter Vilmann

Chairman of the Business, Research and Development Committee

Executive Management Team

Thomas Kaas Selsø

Chief Executive Officer

Connect with us

Pharma Equity Group
Slotsmarken 18, 2.th.
DK-2970 Hørsholm

Contact us at info@pharmaequitygroup.com